Table 2 Baseline patient characteristics in the pre- and post-PSM cohort
| Â | Before PSM | After PSM | ||||
|---|---|---|---|---|---|---|
Characteristics | P67.5 (n = 158) | P70 (n = 216) | P* | P67.5 (n = 148) | P70 (n = 148) | P* |
Gender | Â | Â | 0.537 | Â | Â | 0.896 |
 Male | 114 (72.2%) | 162 (75.0%) |  | 108 (73.0%) | 107 (72.3%) |  |
 Female | 44 (27.8%) | 54 (25.0%) |  | 40 (27.0%) | 41 (27.7%) |  |
Age (years) | Â | Â | 0.434 | Â | Â | 0.444 |
 Median (range) | 47 (15–75) | 44 (10–81) |  | 47 (15–75) | 45 (10–81) |  |
 Mean (SD) | 45.5 (13.5) | 44.4 (13.9) |  | 45.7 (13.0) | 44.3 (13.8) |  |
T stage | Â | Â | 0.485 | Â | Â | 0.822 |
 1 | 41 (25.9%) | 63 (29.2%) |  | 41 (27.7%) | 46 (31.1%) |  |
 2 | 49 (31.0%) | 71 (32.9%) |  | 48 (32.4%) | 41 (27.7%) |  |
 3 | 43 (27.2%) | 44 (20.4%) |  | 34 (23.0%) | 34 (23.0%) |  |
 4 | 25 (15.8%) | 38 (17.6%) |  | 25 (16.9%) | 27 (18.2%) |  |
N stage | Â | Â | 0.014 | Â | Â | 0.985 |
 0 | 21 (13.3%) | 46 (21.3%) |  | 21 (14.2%) | 22 (14.9%) |  |
 1 | 50 (31.6%) | 85 (39.4%) |  | 50 (33.8%) | 51 (34.5%) |  |
 2 | 77 (48.7%) | 71 (32.9%) |  | 68 (45.9%) | 65 (43.9%) |  |
 3 | 10 (6.3%) | 14 (6.5%) |  | 9 (6.1%) | 10 (6.8%) |  |
Clinical stage | Â | Â | 0.017 | Â | Â | 0.829 |
 I | 7 (4.4%) | 16 (7.4%) |  | 7 (4.7%) | 8 (5.4%) |  |
 II | 36 (22.8%) | 72 (33.3%) |  | 36 (24.3%) | 39 (26.4%) |  |
 III | 80 (50.6%) | 76 (35.2%) |  | 71 (48.0%) | 63 (42.6%) |  |
 IVa | 35 (22.2%) | 52 (24.1%) |  | 34 (23.0%) | 38 (25.7%) |  |